These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 8324747)
1. p53 is mutated in a subset of advanced-stage prostate cancers. Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747 [TBL] [Abstract][Full Text] [Related]
2. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467 [TBL] [Abstract][Full Text] [Related]
3. Association of p53 mutations with metastatic prostate cancer. Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901 [TBL] [Abstract][Full Text] [Related]
4. [Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer]. Castagnaro M; Yandell DW; Dockhorn-Dworniczak B; Wolfe HJ; Poremba C Verh Dtsch Ges Pathol; 1993; 77():119-23. PubMed ID: 7511268 [TBL] [Abstract][Full Text] [Related]
5. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Suzuki H; Komiya A; Aida S; Ito H; Yatani R; Shimazaki J Prostate; 1996 May; 28(5):318-24. PubMed ID: 8610059 [TBL] [Abstract][Full Text] [Related]
6. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413 [TBL] [Abstract][Full Text] [Related]
7. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE). Schlechte HH; Schnorr D; Löning T; Rudolph BD; Pohrt UM; Loening SA J Urol; 1997 Mar; 157(3):1049-53. PubMed ID: 9072541 [TBL] [Abstract][Full Text] [Related]
8. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Kishimoto Y; Murakami Y; Shiraishi M; Hayashi K; Sekiya T Cancer Res; 1992 Sep; 52(17):4799-804. PubMed ID: 1324794 [TBL] [Abstract][Full Text] [Related]
9. An uncertain role for p53 gene alterations in human prostate cancers. Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029 [TBL] [Abstract][Full Text] [Related]
10. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Meyers FJ; Gumerlock PH; Chi SG; Borchers H; Deitch AD; deVere White RW Cancer; 1998 Dec; 83(12):2534-9. PubMed ID: 9874460 [TBL] [Abstract][Full Text] [Related]
11. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Stapleton AM; Timme TL; Gousse AE; Li QF; Tobon AA; Kattan MW; Slawin KM; Wheeler TM; Scardino PT; Thompson TC Clin Cancer Res; 1997 Aug; 3(8):1389-97. PubMed ID: 9815823 [TBL] [Abstract][Full Text] [Related]
12. p53 protein and gene alterations in pathological stage C prostate carcinoma. Salem CE; Tomasic NA; Elmajian DA; Esrig D; Nichols PW; Taylor CR; Skinner DG; Roy-Burman P; Lieskovsky G; Cote RJ J Urol; 1997 Aug; 158(2):510-4. PubMed ID: 9224335 [TBL] [Abstract][Full Text] [Related]
13. Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms. Yamaguchi K; Sugano K; Fukayama N; Nakashima Y; Saotome K; Yokoyama T; Yokota T; Ohkura H Am J Gastroenterol; 1997 Feb; 92(2):307-12. PubMed ID: 9040212 [TBL] [Abstract][Full Text] [Related]
14. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024 [TBL] [Abstract][Full Text] [Related]
15. Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particles. Andersson M; Jönsson M; Nielsen LL; Vyberg M; Visfeldt J; Storm HH; Wallin H Cancer Epidemiol Biomarkers Prev; 1995; 4(7):765-70. PubMed ID: 8672994 [TBL] [Abstract][Full Text] [Related]
17. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Isaacs WB; Carter BS; Ewing CM Cancer Res; 1991 Sep; 51(17):4716-20. PubMed ID: 1873816 [TBL] [Abstract][Full Text] [Related]
18. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641 [TBL] [Abstract][Full Text] [Related]
19. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163 [TBL] [Abstract][Full Text] [Related]
20. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. Navone NM; Labate ME; Troncoso P; Pisters LL; Conti CJ; von Eschenbach AC; Logothetis CJ J Urol; 1999 Jan; 161(1):304-8. PubMed ID: 10037428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]